Senseonics (NYSE:SENS) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Senseonics (NYSE:SENS) in a report released on Friday. The brokerage set a “sell” rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $2.00 target price on shares of Senseonics in a research report on Wednesday, August 14th.

Senseonics Stock Performance

NYSE SENS opened at $0.41 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.11 and a debt-to-equity ratio of 59.17. The stock has a market cap of $217.92 million, a price-to-earnings ratio of -2.91 and a beta of 0.80. Senseonics has a fifty-two week low of $0.32 and a fifty-two week high of $0.75. The business has a fifty day moving average of $0.41 and a 200-day moving average of $0.46.

Senseonics (NYSE:SENS) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). Senseonics had a negative net margin of 335.15% and a negative return on equity of 299.69%. The business had revenue of $4.87 million during the quarter, compared to the consensus estimate of $4.86 million. As a group, analysts predict that Senseonics will post -0.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Senseonics

Several hedge funds and other institutional investors have recently modified their holdings of SENS. Vanguard Group Inc. increased its position in Senseonics by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock valued at $11,963,000 after acquiring an additional 155,715 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Senseonics by 30.2% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock valued at $483,000 after purchasing an additional 211,128 shares during the period. Cubist Systematic Strategies LLC grew its holdings in Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after acquiring an additional 85,501 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Senseonics by 16.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after acquiring an additional 51,000 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Senseonics during the 1st quarter valued at about $162,000. Institutional investors and hedge funds own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.